sibutramine has been researched along with Insulin Sensitivity in 39 studies
sibutramine: serotonin and norepinephrine transporter inhibitor; Meridia is tradename for sibutramine hydrochloride
| Excerpt | Relevance | Reference |
|---|---|---|
| "Body weight reduction was greater in the sibutramine group." | 9.16 | Sibutramine administration decreases serum anti-Müllerian hormone (AMH) levels in women with polycystic ovary syndrome. ( Armeni, AK; Georgopoulos, NA; Katsikis, I; Panidis, D; Papadakis, E; Roupas, ND; Vosnakis, C, 2012) |
| "Sibutramine plus L-carnitine gave a faster improvement of lipid profile, insulin resistance parameters, glycemic control, and body weight compared to sibutramine." | 9.14 | Sibutramine and L-carnitine compared to sibutramine alone on insulin resistance in diabetic patients. ( Cicero, AF; D'Angelo, A; Derosa, G; Ferrari, I; Gravina, A; Maffioli, P; Mereu, R; Palumbo, I; Randazzo, S; Salvadeo, SA, 2010) |
| "Sibutramine gave a faster improvement of insulin resistance parameters and glycemic control compared to placebo; furthermore sibutramine gave also an improvement of lipid profile, and body weight." | 9.14 | Effects of one year treatment of sibutramine on insulin resistance parameters in type 2 diabetic patients. ( Cicero, AF; D'Angelo, A; Derosa, G; Ferrari, I; Maffioli, P; Palumbo, I; Randazzo, S, 2010) |
| "Body weight reduced in both groups but the reduction was greater with sibutramine (-15." | 9.13 | Effect of hypocaloric diet plus sibutramine treatment on hormonal and metabolic features in overweight and obese women with polycystic ovary syndrome: a randomized, 24-week study. ( Diamanti-Kandarakis, E; Florakis, D; Georgopoulos, N; Karkanaki, A; Katsikis, I; Nassis, GP; Panidis, D, 2008) |
| "The aim of this study was to evaluate the effects of sibutramine on body composition and fat distribution, insulin resistance, and serum adiponectin levels in obese women." | 9.11 | Sibutramine improves fat distribution and insulin resistance, and increases serum adiponectin levels in Korean obese nondiabetic premenopausal women. ( Ahn, CW; Cha, BS; Huh, KB; Kim, DM; Kim, KR; Lee, HC; Lim, SK; Yoon, SJ, 2004) |
| "To evaluate the effects of sibutramine on body weight, body fat mass, metabolism of plasma glucose and serum lipids, and insulin resistance (IR) in primary obesity patients." | 9.11 | [Effects of sibutramine on blood glucose and lipids, body fat mass and insulin resistance in obese patients: a multi-center clinical trial]. ( Li, QF; Li, R; Li, XJ; Liu, YP; Ran, XW; Tang, BD; Tong, NW; Yang, FY, 2005) |
| " The effect of sibutramine combined with hypocaloric diet and exercise on body weight, body fat mass, lipids, glycemic control, insulin secretion and insulin resistance was evaluated in a randomized, controlled, open-label study." | 9.11 | Sibutramine in the treatment of obesity in type 2 diabetic patients and in nondiabetic subjects. ( Dakovska, G; Dakovska, L; Kirilov, G; Koev, D; Lazarova, M; Tankova, T, 2004) |
| "Sibutramine therapy induced greater body weight loss than placebo in hypertensive obese patients." | 9.11 | Effects of sibutramine on abdominal fat mass, insulin resistance and blood pressure in obese hypertensive patients. ( Faria, AN; Gouvea Ferreira, SR; Kohlmann, NE; Ribeiro Filho, FF; Zanella, MT, 2005) |
| "Sibutramine has demonstrated efficacy in reducing weight in non-diabetic women along with amelioration in insulin sensitivity and additional improvement in metabolic parameters." | 9.10 | Sibutramine enhances insulin sensitivity ameliorating metabolic parameters in a double-blind, randomized, placebo-controlled trial. ( Geloneze, B; Geloneze, SR; Magro, DO; Picolo, M; Repetto, EM; Tambascia, MA, 2003) |
| "To assess the relationship between serum leptin and insulin resistance (IR) in obesity, and to investigate the effects of sibutramine on obesity, serum leptin and IR." | 9.10 | [Serum leptin and insulin resistance in obesity and effects of sibutramine on them]. ( Chen, HL; Lei, MX; Wu, J, 2003) |
| "The present study shows that both sibutramine-induced and orlistat-induced weight losses result in reduction of insulin resistance, and improvements in biochemical markers and US findings of NASH." | 9.10 | The effects of sibutramine and orlistat on the ultrasonographic findings, insulin resistance and liver enzyme levels in obese patients with non-alcoholic steatohepatitis. ( Karaoglanoglu, M; Kilic, FB; Nazligul, Y; Sabuncu, T; Ucar, E, 2003) |
| "Topiramate is newly approved as anticonvulsant that seems to promote body weight loss in humans." | 7.77 | Topiramate induces weight loss and improves insulin sensitivity in dietary obese rats: comparison to sibutramine. ( Abo-Elmatty, DM; Zaitone, SA, 2011) |
| "Weight loss with sibutramine was associated with improvements in metabolic and body composition risk factors but not blood pressure or arterial stiffness." | 7.75 | Changes in regional adiposity and cardio-metabolic function following a weight loss program with sibutramine in obese men with obstructive sleep apnea. ( Banerjee, D; Berend, N; Grunstein, RR; Magnussen, JS; Phillips, CL; Trenell, MI; Wang, D; Yee, BJ, 2009) |
| "The relationship between insulin-mediated glucose disposal and daylong free fatty acid (FFA) concentrations before and after sibutramine-assisted weight loss was investigated in 24 healthy, normotensive, nondiabetic, obese women (body mass index [BMI] >30." | 7.71 | Metabolic changes following sibutramine-assisted weight loss in obese individuals: role of plasma free fatty acids in the insulin resistance of obesity. ( Abbasi, F; Kim, HS; Lamendola, C; McLaughlin, T; Reaven, GM, 2001) |
| "We studied the effects of the novel noradrenaline and serotonin (5-HT) reuptake inhibitor sibutramine on feeding and body weight in a rat model of dietary obesity, and whether it interacts with hypothalamic neuropeptide Y (NPY) neurones." | 7.71 | Sibutramine reduces feeding, body fat and improves insulin resistance in dietary-obese male Wistar rats independently of hypothalamic neuropeptide Y. ( Bing, C; Brown, M; Heal, D; King, P; Pickavance, L; Wilding, J, 2001) |
| "The results indicate that chronic administration of sibutramine can reduce weight gain, lower NEFA concentrations, decrease hyperinsulinaemia and ameliorate the insulin resistance of ob/ob mice." | 7.70 | Effect of the antiobesity agent sibutramine in obese-diabetic ob/ob mice. ( Bailey, CJ; Day, C, 1998) |
| "The treatment of obesity is strongly recommended because many studies have shown it to be a strong risk factor for cardiovascular disease." | 6.71 | The effect of 1-yr sibutramine treatment on glucose tolerance, insulin sensitivity and serum lipid profiles in obese subjects. ( Birden, F; Sabuncu, T; Ucar, E; Yasar, O, 2004) |
| "Body weight reduction was greater in the sibutramine group." | 5.16 | Sibutramine administration decreases serum anti-Müllerian hormone (AMH) levels in women with polycystic ovary syndrome. ( Armeni, AK; Georgopoulos, NA; Katsikis, I; Panidis, D; Papadakis, E; Roupas, ND; Vosnakis, C, 2012) |
| "To develop statistical models for predicting weight loss and regain, we analyzed the phenotypic responses in an outpatient study of 60 obese subjects randomized to one of three 12-week interventions, diet (-600 kcal) alone, diet with exercise, and diet with sibutramine." | 5.16 | Prediction of weight loss and regain following dietary, lifestyle, and pharmacologic intervention. ( Brooke, A; Delafont, B; Elkhawad, M; Miller, SR; Murgatroyd, PR; Napolitano, A; Nunez, DJ; Tan, CY; Vidal-Puig, A; Virtue, S, 2012) |
| "The aim of the study was to evaluate the effects of 12-month treatment with sibutramine plus L-carnitine compared with sibutramine alone on body weight, glycemic control, insulin resistance, and inflammatory state in type 2 diabetes mellitus patients." | 5.15 | Effects of combination of sibutramine and L-carnitine compared with sibutramine monotherapy on inflammatory parameters in diabetic patients. ( Cicero, AF; D'Angelo, A; Derosa, G; Ferrari, I; Gravina, A; Maffioli, P; Mereu, R; Palumbo, I; Randazzo, S; Salvadeo, SA, 2011) |
| "We observed a decrease of body weight after 9 and 12 months in the group treated with sibutramine, but not in the control group." | 5.15 | Variation of inflammatory parameters after sibutramine treatment compared to placebo in type 2 diabetic patients. ( Cicero, AF; D'Angelo, A; Derosa, G; Ferrari, I; Maffioli, P; Palumbo, I; Randazzo, S, 2011) |
| "Sibutramine and metformin are drugs commonly used to obtain weight loss." | 5.14 | Comparison of the effects of sibutramine versus sibutramine plus metformin in obese women. ( Akbas, H; Coban, E; Eray, E; Ozdem, S; Sari, R, 2010) |
| "Sibutramine plus L-carnitine gave a faster improvement of lipid profile, insulin resistance parameters, glycemic control, and body weight compared to sibutramine." | 5.14 | Sibutramine and L-carnitine compared to sibutramine alone on insulin resistance in diabetic patients. ( Cicero, AF; D'Angelo, A; Derosa, G; Ferrari, I; Gravina, A; Maffioli, P; Mereu, R; Palumbo, I; Randazzo, S; Salvadeo, SA, 2010) |
| "Sibutramine gave a faster improvement of insulin resistance parameters and glycemic control compared to placebo; furthermore sibutramine gave also an improvement of lipid profile, and body weight." | 5.14 | Effects of one year treatment of sibutramine on insulin resistance parameters in type 2 diabetic patients. ( Cicero, AF; D'Angelo, A; Derosa, G; Ferrari, I; Maffioli, P; Palumbo, I; Randazzo, S, 2010) |
| "Body weight reduced in both groups but the reduction was greater with sibutramine (-15." | 5.13 | Effect of hypocaloric diet plus sibutramine treatment on hormonal and metabolic features in overweight and obese women with polycystic ovary syndrome: a randomized, 24-week study. ( Diamanti-Kandarakis, E; Florakis, D; Georgopoulos, N; Karkanaki, A; Katsikis, I; Nassis, GP; Panidis, D, 2008) |
| "The aim of this study was to evaluate the effects of sibutramine on body composition and fat distribution, insulin resistance, and serum adiponectin levels in obese women." | 5.11 | Sibutramine improves fat distribution and insulin resistance, and increases serum adiponectin levels in Korean obese nondiabetic premenopausal women. ( Ahn, CW; Cha, BS; Huh, KB; Kim, DM; Kim, KR; Lee, HC; Lim, SK; Yoon, SJ, 2004) |
| " The effect of sibutramine combined with hypocaloric diet and exercise on body weight, body fat mass, lipids, glycemic control, insulin secretion and insulin resistance was evaluated in a randomized, controlled, open-label study." | 5.11 | Sibutramine in the treatment of obesity in type 2 diabetic patients and in nondiabetic subjects. ( Dakovska, G; Dakovska, L; Kirilov, G; Koev, D; Lazarova, M; Tankova, T, 2004) |
| "Sibutramine therapy induced greater body weight loss than placebo in hypertensive obese patients." | 5.11 | Effects of sibutramine on abdominal fat mass, insulin resistance and blood pressure in obese hypertensive patients. ( Faria, AN; Gouvea Ferreira, SR; Kohlmann, NE; Ribeiro Filho, FF; Zanella, MT, 2005) |
| "To evaluate the effects of sibutramine on body weight, body fat mass, metabolism of plasma glucose and serum lipids, and insulin resistance (IR) in primary obesity patients." | 5.11 | [Effects of sibutramine on blood glucose and lipids, body fat mass and insulin resistance in obese patients: a multi-center clinical trial]. ( Li, QF; Li, R; Li, XJ; Liu, YP; Ran, XW; Tang, BD; Tong, NW; Yang, FY, 2005) |
| "Aim of this study was to compare the effects of metformin and a body weight reduction regimen using sibutramine on insulinemia, insulin sensitivity, and ovarian function in women with anovulatory cycles or infertility." | 5.11 | Metformin versus sibutramine in the treatment of hyperinsulinemia in chronically anovulating women. ( Dravecka, I; Kraus, V; Lazurova, I; Petrovicova, J, 2004) |
| "To assess the relationship between serum leptin and insulin resistance (IR) in obesity, and to investigate the effects of sibutramine on obesity, serum leptin and IR." | 5.10 | [Serum leptin and insulin resistance in obesity and effects of sibutramine on them]. ( Chen, HL; Lei, MX; Wu, J, 2003) |
| "The present study shows that both sibutramine-induced and orlistat-induced weight losses result in reduction of insulin resistance, and improvements in biochemical markers and US findings of NASH." | 5.10 | The effects of sibutramine and orlistat on the ultrasonographic findings, insulin resistance and liver enzyme levels in obese patients with non-alcoholic steatohepatitis. ( Karaoglanoglu, M; Kilic, FB; Nazligul, Y; Sabuncu, T; Ucar, E, 2003) |
| "Sibutramine has demonstrated efficacy in reducing weight in non-diabetic women along with amelioration in insulin sensitivity and additional improvement in metabolic parameters." | 5.10 | Sibutramine enhances insulin sensitivity ameliorating metabolic parameters in a double-blind, randomized, placebo-controlled trial. ( Geloneze, B; Geloneze, SR; Magro, DO; Picolo, M; Repetto, EM; Tambascia, MA, 2003) |
| "Weight loss following sibutramine administration is associated with several favourable metabolic effects." | 4.82 | A review of the metabolic effects of sibutramine. ( Elisaf, MS; Filippatos, TD; Kiortsis, DN; Liberopoulos, EN; Mikhailidis, DP, 2005) |
| "Topiramate is newly approved as anticonvulsant that seems to promote body weight loss in humans." | 3.77 | Topiramate induces weight loss and improves insulin sensitivity in dietary obese rats: comparison to sibutramine. ( Abo-Elmatty, DM; Zaitone, SA, 2011) |
| "Weight loss with sibutramine was associated with improvements in metabolic and body composition risk factors but not blood pressure or arterial stiffness." | 3.75 | Changes in regional adiposity and cardio-metabolic function following a weight loss program with sibutramine in obese men with obstructive sleep apnea. ( Banerjee, D; Berend, N; Grunstein, RR; Magnussen, JS; Phillips, CL; Trenell, MI; Wang, D; Yee, BJ, 2009) |
| "We studied the effects of the novel noradrenaline and serotonin (5-HT) reuptake inhibitor sibutramine on feeding and body weight in a rat model of dietary obesity, and whether it interacts with hypothalamic neuropeptide Y (NPY) neurones." | 3.71 | Sibutramine reduces feeding, body fat and improves insulin resistance in dietary-obese male Wistar rats independently of hypothalamic neuropeptide Y. ( Bing, C; Brown, M; Heal, D; King, P; Pickavance, L; Wilding, J, 2001) |
| "The anti-obesity agent sibutramine, a serotonin and noradrenaline reuptake inhibitor (SNRI), has been shown to reduce insulin resistance and improve glycaemic control in obese-diabetic ob/ob mice and overweight type 2 diabetic patients." | 3.71 | Sibutramine metabolites increase glucose transport by cultured rat muscle cells. ( Bailey, CJ; Bates, SH; Jones, RB; Turner, SL, 2001) |
| "The relationship between insulin-mediated glucose disposal and daylong free fatty acid (FFA) concentrations before and after sibutramine-assisted weight loss was investigated in 24 healthy, normotensive, nondiabetic, obese women (body mass index [BMI] >30." | 3.71 | Metabolic changes following sibutramine-assisted weight loss in obese individuals: role of plasma free fatty acids in the insulin resistance of obesity. ( Abbasi, F; Kim, HS; Lamendola, C; McLaughlin, T; Reaven, GM, 2001) |
| "The results indicate that chronic administration of sibutramine can reduce weight gain, lower NEFA concentrations, decrease hyperinsulinaemia and ameliorate the insulin resistance of ob/ob mice." | 3.70 | Effect of the antiobesity agent sibutramine in obese-diabetic ob/ob mice. ( Bailey, CJ; Day, C, 1998) |
| " The first group received three daily 120 mg dosages of orlistat for nine months (n=39), and the second group received a once daily 10 or 15 mg dosage of sibutramine for nine months (n=37)." | 2.84 | Metabolic and Inflammatory Changes with Orlistat and Sibutramine Treatment in Obese Malaysian Subjects. ( Al-Safi Ismail, AA; Al-Tahami, BAM; Rasool, AHG; Sanip, Z; Shihabudin, TMT; Singh, TSP; Yusoff, Z, 2017) |
| "Five hundred and seventy-six consecutive Caucasian obese type 2 diabetic patients were evaluated during a 12-months period and fifty-two patients were resulted intolerant to metformin at maximum dosage (3,000 mg/day)." | 2.74 | Pioglitazone metabolic effect in metformin-intolerant obese patients treated with sibutramine. ( Ciccarelli, L; Cicero, AF; D'Angelo, A; Derosa, G; Ferrari, I; Gravina, A; Maffioli, P; Mereu, R; Piccinni, MN; Salvadeo, SA, 2009) |
| "The treatment of obesity is strongly recommended because many studies have shown it to be a strong risk factor for cardiovascular disease." | 2.71 | The effect of 1-yr sibutramine treatment on glucose tolerance, insulin sensitivity and serum lipid profiles in obese subjects. ( Birden, F; Sabuncu, T; Ucar, E; Yasar, O, 2004) |
| "Sibutramine has been shown to exert favorable effects on some surrogate cardiovascular endpoints such as reduction of left ventricular hypertrophy and improvement of endothelial dysfunction." | 2.46 | Cardiovascular risk-benefit profile of sibutramine. ( Scheen, AJ, 2010) |
| "Obesity is associated with significant increase in cardiovascular risk." | 2.43 | The obesity epidemic and its cardiovascular consequences. ( Behn, A; Ur, E, 2006) |
| "After 14 weeks of treatment, body weight, abdominal fat, blood lipid and serum insulin level were measured, and the protein and gene expression of PTP1B in liver tissue was tested." | 1.37 | Hepatic PTP1B expression involvement in the effects of Chinese medicine formula xiao-gao-jiang-zhuo using an obese rat model. ( Chang, B; Li, M; Liu, WK; Qin, PJ; Tong, XL; Zhen, Z, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (2.56) | 18.2507 |
| 2000's | 24 (61.54) | 29.6817 |
| 2010's | 14 (35.90) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Shin, HY | 1 |
| Park, S | 1 |
| Lee, JW | 2 |
| Al-Tahami, BAM | 1 |
| Al-Safi Ismail, AA | 1 |
| Sanip, Z | 1 |
| Yusoff, Z | 1 |
| Shihabudin, TMT | 1 |
| Singh, TSP | 1 |
| Rasool, AHG | 1 |
| Derosa, G | 6 |
| D'Angelo, A | 6 |
| Salvadeo, SA | 4 |
| Ferrari, I | 6 |
| Gravina, A | 4 |
| Fogari, E | 1 |
| Maffioli, P | 6 |
| Cicero, AF | 6 |
| Rihmer, Z | 1 |
| Purebl, G | 1 |
| Faludi, G | 1 |
| Halmy, L | 1 |
| Mereu, R | 3 |
| Ciccarelli, L | 1 |
| Piccinni, MN | 1 |
| Georgopoulos, NA | 2 |
| Katsikis, I | 3 |
| Florakis, D | 2 |
| Panidis, D | 3 |
| Kandarakis, ED | 1 |
| Sari, R | 1 |
| Eray, E | 1 |
| Ozdem, S | 1 |
| Akbas, H | 1 |
| Coban, E | 1 |
| Phillips, CL | 1 |
| Yee, BJ | 1 |
| Trenell, MI | 1 |
| Magnussen, JS | 1 |
| Wang, D | 1 |
| Banerjee, D | 1 |
| Berend, N | 1 |
| Grunstein, RR | 1 |
| Palumbo, I | 4 |
| Randazzo, S | 4 |
| Madsen, AN | 1 |
| Hansen, G | 2 |
| Paulsen, SJ | 1 |
| Lykkegaard, K | 1 |
| Tang-Christensen, M | 1 |
| Hansen, HS | 1 |
| Levin, BE | 1 |
| Larsen, PJ | 1 |
| Knudsen, LB | 1 |
| Fosgerau, K | 1 |
| Vrang, N | 2 |
| Scheen, AJ | 1 |
| Li, M | 1 |
| Chang, B | 1 |
| Zhen, Z | 1 |
| Qin, PJ | 1 |
| Liu, WK | 1 |
| Tong, XL | 1 |
| Abo-Elmatty, DM | 1 |
| Zaitone, SA | 1 |
| Jelsing, J | 1 |
| Napolitano, A | 1 |
| Miller, SR | 1 |
| Murgatroyd, PR | 1 |
| Delafont, B | 1 |
| Brooke, A | 1 |
| Elkhawad, M | 1 |
| Tan, CY | 1 |
| Virtue, S | 1 |
| Vidal-Puig, A | 1 |
| Nunez, DJ | 1 |
| Vosnakis, C | 1 |
| Armeni, AK | 1 |
| Papadakis, E | 1 |
| Roupas, ND | 1 |
| Tambascia, MA | 1 |
| Geloneze, B | 1 |
| Repetto, EM | 1 |
| Geloneze, SR | 1 |
| Picolo, M | 1 |
| Magro, DO | 1 |
| Sabuncu, T | 2 |
| Nazligul, Y | 1 |
| Karaoglanoglu, M | 1 |
| Ucar, E | 2 |
| Kilic, FB | 1 |
| Birden, F | 1 |
| Yasar, O | 1 |
| Lazurova, I | 1 |
| Dravecka, I | 1 |
| Kraus, V | 1 |
| Petrovicova, J | 1 |
| Kim, DM | 1 |
| Yoon, SJ | 1 |
| Ahn, CW | 1 |
| Cha, BS | 1 |
| Lim, SK | 1 |
| Kim, KR | 1 |
| Lee, HC | 1 |
| Huh, KB | 1 |
| Tankova, T | 1 |
| Dakovska, G | 1 |
| Lazarova, M | 1 |
| Dakovska, L | 1 |
| Kirilov, G | 1 |
| Koev, D | 1 |
| Wu, J | 1 |
| Lei, MX | 1 |
| Chen, HL | 1 |
| Faria, AN | 1 |
| Ribeiro Filho, FF | 1 |
| Kohlmann, NE | 1 |
| Gouvea Ferreira, SR | 1 |
| Zanella, MT | 1 |
| Filippatos, TD | 1 |
| Kiortsis, DN | 1 |
| Liberopoulos, EN | 1 |
| Mikhailidis, DP | 1 |
| Elisaf, MS | 1 |
| Tong, NW | 1 |
| Ran, XW | 1 |
| Li, QF | 1 |
| Tang, BD | 1 |
| Li, R | 1 |
| Yang, FY | 1 |
| Liu, YP | 1 |
| Li, XJ | 1 |
| Behn, A | 1 |
| Ur, E | 1 |
| Dalmau Serra, J | 1 |
| Alonso Franch, M | 1 |
| Gómez López, L | 1 |
| Martínez Costa, C | 1 |
| Sierra Salinas, C | 1 |
| Diamanti-Kandarakis, E | 1 |
| Nassis, GP | 1 |
| Karkanaki, A | 1 |
| Georgopoulos, N | 1 |
| Lee, HR | 1 |
| Shim, JY | 1 |
| Im, JA | 1 |
| Lee, DC | 1 |
| Day, C | 1 |
| Bailey, CJ | 2 |
| Brown, M | 1 |
| Bing, C | 1 |
| King, P | 1 |
| Pickavance, L | 1 |
| Heal, D | 1 |
| Wilding, J | 1 |
| Turner, SL | 1 |
| Bates, SH | 1 |
| Jones, RB | 1 |
| McLaughlin, T | 2 |
| Abbasi, F | 2 |
| Kim, HS | 2 |
| Lamendola, C | 2 |
| Schaaf, P | 1 |
| Reaven, G | 1 |
| Reaven, GM | 1 |
| Gokcel, A | 1 |
| Gumurdulu, Y | 1 |
| Karakose, H | 1 |
| Karademir, BM | 1 |
| Anarat, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Progressive Weight Loss and Metabolic Health[NCT01299519] | 59 participants (Actual) | Interventional | 2011-02-28 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 reviews available for sibutramine and Insulin Sensitivity
| Article | Year |
|---|---|
[Association of obesity and depression].
Topics: Anti-Obesity Agents; Antidepressive Agents; Appetite Depressants; Appetite Regulation; Bipolar Disor | 2008 |
Cardiovascular risk-benefit profile of sibutramine.
Topics: Appetite Depressants; Blood Pressure; Cardiovascular Diseases; Cholesterol, HDL; Cyclobutanes; Gluco | 2010 |
A review of the metabolic effects of sibutramine.
Topics: Appetite Depressants; Blood Glucose; Cholesterol; Cyclobutanes; Diabetes Mellitus, Type 2; Glycated | 2005 |
The obesity epidemic and its cardiovascular consequences.
Topics: Appetite Depressants; Body Fat Distribution; Body Mass Index; Cardiovascular Diseases; Cyclobutanes; | 2006 |
[Childhood obesity. Recommendations of the Nutrition Committee of the Spanish Association of Pediatrics. Part II. Diagnosis. Comorbidities. Treatment].
Topics: Anti-Obesity Agents; Appetite Depressants; Cardiovascular Diseases; Child; Combined Modality Therapy | 2007 |
21 trials available for sibutramine and Insulin Sensitivity
| Article | Year |
|---|---|
Metabolic and Inflammatory Changes with Orlistat and Sibutramine Treatment in Obese Malaysian Subjects.
Topics: Adiponectin; Adolescent; Adult; Aged; Asian People; Blood Glucose; Body Fat Distribution; Body Mass | 2017 |
Sibutramine effect on metabolic control of obese patients with type 2 diabetes mellitus treated with pioglitazone.
Topics: Appetite Depressants; Blood Glucose; Blood Pressure; Body Mass Index; Cholesterol, HDL; Cyclobutanes | 2008 |
Pioglitazone metabolic effect in metformin-intolerant obese patients treated with sibutramine.
Topics: Appetite Depressants; Blood Glucose; Blood Pressure; Cyclobutanes; Diabetes Mellitus, Type 2; Double | 2009 |
Comparison of the effects of sibutramine versus sibutramine plus metformin in obese women.
Topics: Adult; Appetite Depressants; C-Reactive Protein; Cyclobutanes; Drug Therapy, Combination; Female; Hu | 2010 |
Effects of combination of sibutramine and L-carnitine compared with sibutramine monotherapy on inflammatory parameters in diabetic patients.
Topics: Aged; Appetite Depressants; Blood Glucose; Body Weight; C-Reactive Protein; Carnitine; Cholesterol; | 2011 |
Sibutramine and L-carnitine compared to sibutramine alone on insulin resistance in diabetic patients.
Topics: Blood Glucose; Carnitine; Cyclobutanes; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy | 2010 |
Variation of inflammatory parameters after sibutramine treatment compared to placebo in type 2 diabetic patients.
Topics: Adiponectin; Appetite Depressants; Blood Glucose; Body Mass Index; Body Weight; C-Reactive Protein; | 2011 |
Effects of one year treatment of sibutramine on insulin resistance parameters in type 2 diabetic patients.
Topics: Adult; Aged; Aged, 80 and over; Appetite Depressants; Blood Glucose; Body Mass Index; Body Weight; C | 2010 |
Prediction of weight loss and regain following dietary, lifestyle, and pharmacologic intervention.
Topics: Absorptiometry, Photon; Adult; Appetite Depressants; Body Composition; Body Weight; Calorimetry, Ind | 2012 |
Sibutramine administration decreases serum anti-Müllerian hormone (AMH) levels in women with polycystic ovary syndrome.
Topics: Adult; Anthropometry; Anti-Mullerian Hormone; Appetite Depressants; Caloric Restriction; Cyclobutane | 2012 |
Sibutramine enhances insulin sensitivity ameliorating metabolic parameters in a double-blind, randomized, placebo-controlled trial.
Topics: Adult; Appetite Depressants; Blood Pressure; Body Composition; Cyclobutanes; Double-Blind Method; Fe | 2003 |
The effects of sibutramine and orlistat on the ultrasonographic findings, insulin resistance and liver enzyme levels in obese patients with non-alcoholic steatohepatitis.
Topics: Adult; Anti-Obesity Agents; Appetite Depressants; Cyclobutanes; Enzyme Inhibitors; Fatty Liver; Fema | 2003 |
The effect of 1-yr sibutramine treatment on glucose tolerance, insulin sensitivity and serum lipid profiles in obese subjects.
Topics: Adolescent; Adult; Appetite Depressants; Blood Glucose; Body Constitution; Body Mass Index; Body Wei | 2004 |
Metformin versus sibutramine in the treatment of hyperinsulinemia in chronically anovulating women.
Topics: Adult; Anovulation; Appetite Depressants; Body Mass Index; Chronic Disease; Cyclobutanes; Diet, Redu | 2004 |
Sibutramine improves fat distribution and insulin resistance, and increases serum adiponectin levels in Korean obese nondiabetic premenopausal women.
Topics: Adiponectin; Adipose Tissue; Adult; Appetite Depressants; Body Mass Index; Cyclobutanes; Humans; Ins | 2004 |
Sibutramine in the treatment of obesity in type 2 diabetic patients and in nondiabetic subjects.
Topics: Adipose Tissue; Adult; Appetite Depressants; Blood Glucose; Body Weight; Cyclobutanes; Diabetes Mell | 2004 |
[Serum leptin and insulin resistance in obesity and effects of sibutramine on them].
Topics: Adolescent; Adult; Appetite Depressants; Body Mass Index; Cyclobutanes; Double-Blind Method; Female; | 2003 |
Effects of sibutramine on abdominal fat mass, insulin resistance and blood pressure in obese hypertensive patients.
Topics: Adult; Antihypertensive Agents; Appetite Depressants; Chi-Square Distribution; Cyclobutanes; Drug Th | 2005 |
[Effects of sibutramine on blood glucose and lipids, body fat mass and insulin resistance in obese patients: a multi-center clinical trial].
Topics: Adolescent; Adult; Aged; Appetite Depressants; Blood Glucose; Body Mass Index; Cyclobutanes; Double- | 2005 |
Effect of hypocaloric diet plus sibutramine treatment on hormonal and metabolic features in overweight and obese women with polycystic ovary syndrome: a randomized, 24-week study.
Topics: Adolescent; Adult; Androgens; Anthropometry; Appetite Depressants; Blood Glucose; Body Fat Distribut | 2008 |
Effects of sibutramine in non-dieting obese women.
Topics: Adult; Appetite Depressants; Blood Glucose; Body Mass Index; C-Peptide; Cyclobutanes; Female; Glucos | 2002 |
13 other studies available for sibutramine and Insulin Sensitivity
| Article | Year |
|---|---|
Positive association between the changes in chemerin and adiponectin levels after weight reduction.
Topics: Adiponectin; Adult; Anti-Obesity Agents; Appetite Depressants; Biomarkers; Body Mass Index; Chemokin | 2017 |
Effect of sibutramine on weight reduction and insulin resistance in women with polycystic ovary syndrome.
Topics: Appetite Depressants; Body Mass Index; Body Weight; Cyclobutanes; Female; Humans; Insulin Resistance | 2009 |
Changes in regional adiposity and cardio-metabolic function following a weight loss program with sibutramine in obese men with obstructive sleep apnea.
Topics: Adipose Tissue; Adiposity; Adult; Aged; Appetite Depressants; Biomarkers; Cardiovascular Diseases; C | 2009 |
Long-term characterization of the diet-induced obese and diet-resistant rat model: a polygenetic rat model mimicking the human obesity syndrome.
Topics: Analysis of Variance; Animals; Appetite Depressants; Blood Glucose; Cyclobutanes; Diet; Disease Mode | 2010 |
Hepatic PTP1B expression involvement in the effects of Chinese medicine formula xiao-gao-jiang-zhuo using an obese rat model.
Topics: Abdominal Fat; Animals; Anti-Obesity Agents; Body Weight; Cholesterol; Cyclobutanes; Dietary Fats; D | 2011 |
Topiramate induces weight loss and improves insulin sensitivity in dietary obese rats: comparison to sibutramine.
Topics: Animals; Anti-Obesity Agents; Blood Glucose; Blood Pressure; Cyclobutanes; Female; Fructose; Insulin | 2011 |
Effects of liraglutide and sibutramine on food intake, palatability, body weight and glucose tolerance in the gubra DIO-rats.
Topics: Animals; Anti-Obesity Agents; Body Weight; Cyclobutanes; Eating; Glucagon-Like Peptide 1; Glucose To | 2012 |
Abdominal visceral fat reduction is associated with favorable changes of serum retinol binding protein-4 in nondiabetic subjects.
Topics: Adiposity; Adult; Appetite Depressants; Cyclobutanes; Diet, Reducing; Female; Humans; Insulin Resist | 2008 |
Effect of the antiobesity agent sibutramine in obese-diabetic ob/ob mice.
Topics: Animals; Appetite Depressants; Blood Glucose; Cyclobutanes; Diabetes Mellitus; Fatty Acids, Nonester | 1998 |
Sibutramine reduces feeding, body fat and improves insulin resistance in dietary-obese male Wistar rats independently of hypothalamic neuropeptide Y.
Topics: Adipose Tissue; Animals; Appetite Depressants; Body Weight; Cyclobutanes; Diet; Feeding Behavior; Hy | 2001 |
Sibutramine metabolites increase glucose transport by cultured rat muscle cells.
Topics: Animals; Appetite Depressants; Area Under Curve; Biological Transport; Cells, Cultured; Chromones; C | 2001 |
Relationship between insulin resistance, weight loss, and coronary heart disease risk in healthy, obese women.
Topics: Appetite Depressants; Body Mass Index; Coronary Disease; Cyclobutanes; Energy Intake; Fasting; Femal | 2001 |
Metabolic changes following sibutramine-assisted weight loss in obese individuals: role of plasma free fatty acids in the insulin resistance of obesity.
Topics: Adipose Tissue; Appetite Depressants; Blood Glucose; Body Mass Index; Cyclobutanes; Fatty Acids, Non | 2001 |